Replies to post #337451 on NorthWest Biotherapeutics Inc (NWBO)

[jimmy667]

That is right because Corporate management has affirmative duties to shareholders. The one we were discussing was duty to disclose the events that would substantially negatively impact the investment, in public traded companies it must be by SEC Form 8k. Four day rule.
For NWBO this is a little clouded as the FDA endpoint has not been updated and is different than the one in Germany for instance. So there is a strong possibility that IF (because they might not have it yet) they have the Statistical Report of the Data ( not raw data) from the 3rd party statisticians and it meets the revised endpoints but not the old primary on the US Clinical Trial site. Then they can likely hold onto it until the FDA accepts or rejects the new endpoint. However, if they were thinking ahead they may have told the statitician to not complete the report until endpoint was finalized with the FDA